Abstract:Background Increasing evidence has validated the crucial role of alternative splicing (AS) in tumors. However, comprehensive investigations on the entirety of AS and their clinical value in glioblastoma (GBM) are lacking. Methods The AS profiles and clinical survival data related to GBM were obtained from The Cancer Genome Atlas database. Univariate and multivariate Cox regression analyses were performed to identify survival-associated AS events. A risk score was calculated, and prognostic signatures were constructed using seven different types of independent prognostic AS events, respectively. The Kaplan-Meier estimator was used to display the survival of GBM patients. The receiver operating characteristic curve was applied to compare the predictive efficacy of each prognostic signature. Enrichment analysis and protein interactive networks were conducted using the gene symbols of the AS events to investigate important processes in GBM. A splicing network between splicing factors and AS events was constructed to display the potential regulatory mechanism in GBM. Results A total of 2355 survival-associated AS events were identified. The splicing prognostic model revealed that patients in the high-risk group have worse survival rates than those in the low-risk group. The predictive efficacy of each prognostic model showed satisfactory performance; among these, the Alternate Terminator (AT) model showed the best performance at an area under the curve (AUC) of 0.906. Enrichment analysis uncovered that autophagy was the most enriched process of prognostic AS gene symbols in GBM. The protein network revealed that UBC, VHL, KCTD7, FBXL19, RNF7, and UBE2N were the core genes in GBM. The splicing network showed complex regulatory correlations, among which ELAVL2 and SYNE1_AT_78181 were the most correlated (r = -.506). Conclusions Applying the prognostic signatures constructed by independent AS events shows promise for predicting the survival of GBM patients. A splicing regulatory network might be the potential splicing mechanism in GBM.

Progress in Pre-mRNA alternative splicing in gliomas

Functional analysis of the short splicing variant encoded by CHI3L1/YKL-40 in glioblastoma

The evolution of alternative splicing in glioblastoma under therapy

Landscape of Alternative Splicing Events Related to Prognosis and Immune Infiltration in Glioma: A Data Analysis and Basic Verification

Identification of Differential Splicing Genes in Gliomas Using Exon Expression Profiling.

Alternative Splicing in Glioblastoma and its Clinical Implication in Outcome Prediction

SRSF3-Regulated RNA Alternative Splicing Promotes Glioblastoma Tumorigenicity by Affecting Multiple Cellular Processes

The systematic identification of survival‐related alternative splicing events and splicing factors in glioblastoma

Systematic Profiling of mRNA Splicing Reveals the Prognostic Predictor and Potential Therapeutic Target for Glioblastoma Multiforme

Comprehensive Characterization of Alternative Mrna Splicing Events in Glioblastoma: Implications for Prognosis, Molecular Subtypes, and Immune Microenvironment Remodeling.

Alternative splicing and cancer: a systematic review

Splicing is an alternate oncogenic pathway activation mechanism in glioma

Computer Analysis of Glioma Transcriptome Profiling: Alternative Splicing Events

Role of alternative splicing signatures in the prognosis of glioblastoma.

The role of alternative pre-mRNA splicing in cancer progression

GLTSCR1 Coordinates Alternative Splicing and Transcription Elongation of ZO1 to Regulate Colorectal Cancer Progression.

Long-range alternative splicing contributes to neoantigen specificity in glioblastoma

RNA splicing analysis deciphers developmental hierarchies and reveals therapeutic targets in adult glioma

A pan-cancer analysis of alternative splicing of splicing factors in 6904 patients

Role of long noncoding RNAs in the regulation of alternative splicing in glioblastoma

Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics